You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Details for New Drug Application (NDA): 217673


✉ Email this page to a colleague

« Back to Dashboard


NDA 217673 describes BRINSUPRI, which is a drug marketed by Insmed Inc and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug. Additional details are available on the BRINSUPRI profile page.

The generic ingredient in BRINSUPRI is brensocatib. One supplier is listed for this compound. Additional details are available on the brensocatib profile page.
Summary for 217673
Tradename:BRINSUPRI
Applicant:Insmed Inc
Ingredient:brensocatib
Patents:14
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 217673
Generic Entry Date for 217673*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 217673
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BRINSUPRI brensocatib TABLET;ORAL 217673 NDA Insmed Incorporated 71558-001 71558-001-30 30 TABLET in 1 BOTTLE (71558-001-30)
BRINSUPRI brensocatib TABLET;ORAL 217673 NDA Insmed Incorporated 71558-002 71558-002-30 30 TABLET in 1 BOTTLE (71558-002-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:Aug 12, 2025TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 12, 2030
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:⤷  Get Started FreePatent Expiration:Jan 21, 2035Product Flag?Substance Flag?YDelist Request?
Patented Use:TREATMENT OF NON-CYSTIC FIBROSIS BRONCHIECTASIS IN PATIENTS 12 YEARS OF AGE AND OLDER
Patent:⤷  Get Started FreePatent Expiration:Jan 21, 2035Product Flag?Substance Flag?YDelist Request?
Patented Use:TREATMENT OF NON-CYSTIC FIBROSIS BRONCHIECTASIS IN PATIENTS 12 YEARS OF AGE AND OLDER

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.